M5717 60 mg + PYRONARIDINE for malaria, falciparum

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 3 Aug 2023: Trial registered, NCT05974267
  2. 28 Nov 2023: Trial started, NCT05974267

The trials

NCT05974267: Efficacy, Safety, and PK of M5717 in Combination With Pyronaridine as Chemoprevention in Adults and Adolescents With Asymptomatic Plasmodium Falciparum Infection (CAPTURE-2)

State
Completed
Phase
Phase 2
People
192 taking part
Started
28 Nov 2023
Primary completion
29 Dec 2024
Arms
Cohort 1: M5717 (60 mg) + Pyronaridine
Results
Posted on the registry
  1. 3 Aug 2023: Trial registered
  2. 28 Nov 2023: Trial started
  3. 29 Dec 2024: Trial completed
  4. 6 Feb 2026: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.